Neurogene, Inc. - Common Stock NGNE 深 滬
已收盤 09-05 16:00:00 美东时间
19.95
+0.340
+1.73%
華盛通- 最 高20.665
- 今 開19.61
- 成交量 19.56万股
- 最 低 19.58
- 昨 收 19.61
- 總市值 2.85亿
- 52周最高 74.49
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 6.875
- 委 比 85.26%
- 總股本 1426.21万
- 歷史最高 362.60
- 量 比 2.45
- 振 幅 5.53%
- 歷史最低 6.875
- 每 手 1
- 風險率 12.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
09-05 02:50
Neurogene Inc. Reports Increased Losses Amid R&D Focus
Neurogene Inc. ( ($NGNE) ) has released its Q2 earnings. Here is a breakdown of...
08-12 12:19
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
An announcement from Neurogene ( ($NGNE) ) is now available. Neurogene Inc. ann...
08-12 07:07
Neurogene GAAP EPS of -$1.05
Neurogene press release (NASDAQ:NGNE): Q2 GAAP EPS of -$1.05. Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 milli...
08-12 04:50
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
08-11 20:45
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
07-30 23:07
美股牛股 | Wolfspeed单日暴涨98%！拟进行破产重组；BitMine公告以太坊储备计划
Wolfspeed单日暴涨98%！拟通过破产重组削减约70%的债务；BitMine隔夜大涨幅35.7%，公告以太坊储备计划>>
07-02 19:38
Neurogene shares are trading higher after the company announced details of its registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older.
Neurogene shares are trading higher after the company announced details of its ...
07-01 22:44
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
